Missouri Attorney General Catherine Hanaway has issued a formal cease-and-desist order to pharmaceutical giant Eli Lilly, signaling a significant escalation in the ongoing legal and regulatory tug-of-war surrounding the federal 340B Drug Pricing Program. In an October 26, 2026, directive, Hanaway accused the Indianapolis-based manufacturer of breaching its legal obligations by conditioning access to mandated discounts on the submission of sensitive claims data. The state’s intervention marks a growing trend of state-level oversight into pharmaceutical supply chains and pricing transparency, putting the manufacturer under intense scrutiny for its evolving distribution policies.
The core of the dispute centers on the 340B program, a federal initiative established by Congress in 1992. Under the Public Health Service Act, drug manufacturers are required to offer outpatient drugs to "covered entities"—which include hospitals serving a large proportion of low-income or uninsured patients—at significantly reduced prices. The objective is to allow these safety-net providers to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.
The Conflict Over Claims Data
For years, the operation of the 340B program relied on a standard pricing model that did not require hospitals to surrender detailed patient-level claims data to manufacturers. However, starting around 2020, several major pharmaceutical companies, including Eli Lilly, began implementing policies that restricted access to these discounts. Specifically, companies began requiring covered entities to upload pharmacy claims data through third-party platforms, such as 340B ESP, as a prerequisite for receiving the statutorily mandated price cuts.
Eli Lilly has historically defended these policies as necessary measures to prevent "duplicate discounts" and to ensure program integrity. The company argues that without visibility into claims, it is impossible to determine whether a drug has already been subject to a Medicaid rebate, which would violate federal law. Conversely, hospitals and health systems argue that these requirements impose an undue administrative burden, compromise patient privacy, and effectively serve as a mechanism to limit the volume of discounted drugs sold.
In her letter, Attorney General Hanaway highlighted the specific case of University of Missouri Health Care. Despite the hospital system’s compliance with the demand to provide the requested claims data, Hanaway asserted that Eli Lilly continued to deny the system the discounts to which it is entitled under federal law. By withholding these savings, Hanaway argued, the company has made "false and misleading statements" to state institutions, thereby violating Missouri’s consumer protection statutes.
Chronology of the 340B Regulatory Impasse
The current standoff is the culmination of years of friction between the pharmaceutical industry and the 340B community. The following timeline captures the evolution of this regulatory landscape:
- 1992: Congress enacts the 340B program, requiring manufacturers to sign a Pharmaceutical Pricing Agreement (PPA) to ensure their products are covered by Medicaid.
- 2020: Several major manufacturers begin restricting 340B pricing for drugs dispensed at contract pharmacies, citing a need for better data transparency.
- 2021-2023: Multiple federal courts issue conflicting rulings regarding the extent to which manufacturers can legally condition 340B discounts on the submission of data.
- 2024: Various states, including Missouri, begin exploring state-level legislative remedies to protect their hospital systems from price hikes associated with the restricted access policies.
- October 26, 2026: Missouri Attorney General Catherine Hanaway issues a cease-and-desist order to Eli Lilly, setting a November 26 deadline for the company to reverse its policy or face further legal action.
Economic Implications for Safety-Net Hospitals
The 340B program is a critical lifeline for health systems. For many hospitals, the savings generated through 340B allow them to fund community health programs, provide charity care, and maintain operations in rural or underserved areas that might otherwise be financially unsustainable.
According to data from the American Hospital Association (AHA), 340B hospitals provide significantly more uncompensated care than non-340B hospitals. When manufacturers limit access to these discounts, the financial impact on these institutions is immediate and profound. If a hospital is forced to pay full wholesale prices for drugs—and then wait for potential reimbursements—its cash flow is constricted, often leading to the reduction of ancillary health services.
Critics of the pharmaceutical industry’s data-collection mandates suggest that these policies are designed to shrink the footprint of the 340B program, effectively reclaiming billions of dollars in revenue that would otherwise remain with hospitals. By creating "hoops" for hospitals to jump through, manufacturers increase the likelihood of administrative errors, which can be used as a pretext for denying discounts.
Official Responses and the Legal Landscape
Eli Lilly has consistently maintained that its policies are consistent with federal law and that it remains committed to the 340B program’s original intent. In response to the Missouri Attorney General’s letter, industry analysts anticipate that the company will likely challenge the scope of state authority. The central question in such a legal battle would be whether federal law governing the 340B program preempts state-level consumer protection laws.
The Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA), which oversees the 340B program, have historically struggled to enforce a unified position on the data-sharing issue. While HRSA has previously suggested that manufacturers do not have the right to impose these conditions, their enforcement actions have been frequently challenged in federal court, leading to a fragmented legal environment where states are now attempting to fill the void.
Broader Impact and Future Outlook
The move by Attorney General Hanaway reflects a broader shift in state-level pharmaceutical policy. States are increasingly viewing drug pricing not just as a federal regulatory matter, but as a public health issue within their own borders. Should Missouri successfully force a change in Eli Lilly’s policy, it could set a powerful legal precedent for other state attorneys general to follow.
The implications for the pharmaceutical industry are significant. If manufacturers are forced to abandon their data-collection requirements, they lose a primary tool for auditing the 340B program. However, if the current trend of state intervention continues, manufacturers may face a "patchwork" of regulations, with different states imposing different requirements, significantly complicating their national distribution strategy.
Furthermore, the involvement of state law enforcement signals a transition from administrative disputes between hospitals and manufacturers to active litigation involving the state as a protector of its institutional interests. For patients, the outcome of this dispute will determine the stability and availability of essential medications at local health clinics. As the November 26 deadline approaches, the industry will be watching closely to see if Eli Lilly chooses to engage in a protracted legal battle in the Missouri courts or if it opts for a negotiated settlement to avoid setting a costly precedent.
Ultimately, the dispute over 340B pricing is a proxy for a larger debate about the role of profit in the healthcare system. While manufacturers prioritize the protection of their intellectual property and the integrity of their pricing models, providers and state officials are prioritizing the preservation of the safety net that supports the nation’s most vulnerable populations. The Missouri cease-and-desist order serves as a sharp reminder that as long as the federal government fails to provide a definitive resolution to these disputes, state-level litigation will continue to define the future of drug pricing in the United States.
Related posts:
